Anti-Human TWEAK receptor Recombinant Antibody (TAB-178)

Customer Review

There are currently no Customer reviews or questions for TAB-178. Click the button above to contact us or submit your feedback about this product.

Citations

1. Vredevoogd, David W., et al. "Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold." Cell 178.3 (2019): 585-599. https://doi.org/10.1016/j.cell.2019.06.014
   This research addresses a significant challenge in cancer immunotherapy by exploring how tumors with low levels of tumor necrosis factor (TNF) can be sensitized to T cell-mediated killing. Through a genome-wide CRISPR/Cas9 screen, the study identified TNF receptor-associated factor 2 (TRAF2) as a critical gatekeeper that regulates tumor sensitivity to T cell-derived TNF. The researchers demonstrated that TRAF2 inactivation dramatically lowers the tumor cytotoxicity threshold to physiologically relevant low TNF concentrations by redirecting TNF signaling toward RIPK1-dependent apoptosis. Clinical data analysis revealed that TNF abundance is generally low in untreated tumors and in non-responders to immune checkpoint blockade (ICB), but rises in responding patients, suggesting that targeting the TNF pathway could enhance ICB efficacy.
   Creative Biolabs provided the agonistic anti-Fn14 antibody (TAB-178) used in this study, which was critical for demonstrating that clustering of Fn14 receptors could sensitize tumor cells to T cell-derived TNF by downregulating TRAF2. This antibody helped the researchers establish that targeted degradation of TRAF2 via the Fn14-TWEAK pathway represents a promising approach for translating their findings toward clinical applications. The combination of TRAF2 targeting (via Fn14 agonism) with cIAP1/2 inhibition demonstrated synergistic enhancement of tumor cell sensitivity to T cell attack, providing a potential new strategy to overcome intrinsic resistance to immunotherapy.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-178, RRID: AB_3111851)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Publications

Our products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of publications that cite this product.

Vredevoogd, David W., et al. "Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold." Cell 178.3 (2019): 585-599.

Biosimilar Overview

Please refer to Enavatuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Enavatuzumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "TNFSF12"

Select a product category from the dropdown menu below to view related products.